FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a method of treating multiple sclerosis in a patient, involving administering to a patient a therapeutically effective amount of (-)5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine or a pharmaceutically acceptable amount thereof salt or solvate.
EFFECT: proposed is a novel method of treating sclerosis based on (-)5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, which shows fewer side effects and which can be administered orally.
15 cl, 8 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS, USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK-INHIBITING ACTIVITY | 2016 |
|
RU2779287C2 |
| METHODS FOR TREATMENT OF BEHAVIOR CHANGES | 2018 |
|
RU2799049C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2681211C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2010 |
|
RU2602814C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2011 |
|
RU2599248C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURONS OR NEURODEGENERATION | 2011 |
|
RU2722018C2 |
| MAIN FATTY ACID ETHERS AND THEIR APPLICATION AS ANTI-INFLAMMATION OR IMMUNOMODULATORY MEDICATIONS | 2003 |
|
RU2337093C2 |
| SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
